Zimmer Partners LP Purchases New Holdings in Sana Biotechnology, Inc. (NASDAQ:SANA)

Zimmer Partners LP bought a new position in shares of Sana Biotechnology, Inc. (NASDAQ:SANA) during the first quarter, according to its most recent Form 13F filing with the SEC. The fund bought 202,500 shares of the company’s stock, valued at approximately $2,025,000.

Other large investors have also recently modified their holdings of the company. Capital World Investors boosted its holdings in Sana Biotechnology by 255.8% in the first quarter. Capital World Investors now owns 5,449,035 shares of the company’s stock valued at $54,490,000 after acquiring an additional 3,917,728 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Sana Biotechnology by 24.1% during the first quarter. Vanguard Group Inc. now owns 12,155,173 shares of the company’s stock worth $121,552,000 after buying an additional 2,358,089 shares during the period. PFM Health Sciences LP raised its stake in Sana Biotechnology by 51.4% during the fourth quarter. PFM Health Sciences LP now owns 1,883,337 shares of the company’s stock worth $7,684,000 after buying an additional 639,198 shares during the last quarter. Baillie Gifford & Co. lifted its holdings in Sana Biotechnology by 5.0% in the first quarter. Baillie Gifford & Co. now owns 10,656,279 shares of the company’s stock valued at $106,563,000 after buying an additional 506,262 shares during the period. Finally, Baker BROS. Advisors LP boosted its position in Sana Biotechnology by 19.0% during the first quarter. Baker BROS. Advisors LP now owns 2,380,949 shares of the company’s stock valued at $23,809,000 after acquiring an additional 380,949 shares during the last quarter. Institutional investors own 88.23% of the company’s stock.

Sana Biotechnology Stock Performance

Shares of NASDAQ SANA traded down $0.73 during trading on Thursday, hitting $5.36. 1,729,153 shares of the company traded hands, compared to its average volume of 2,514,811. The business’s fifty day moving average is $6.30 and its 200 day moving average is $7.57. The firm has a market capitalization of $1.19 billion, a price-to-earnings ratio of -3.54 and a beta of 1.45. Sana Biotechnology, Inc. has a fifty-two week low of $2.74 and a fifty-two week high of $12.00.

Sana Biotechnology (NASDAQ:SANA) last posted its quarterly earnings results on Wednesday, May 8th. The company reported ($0.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.02). On average, analysts predict that Sana Biotechnology, Inc. will post -1.15 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on SANA shares. Rodman & Renshaw initiated coverage on Sana Biotechnology in a research report on Wednesday, June 26th. They issued a “buy” rating and a $16.00 price objective for the company. HC Wainwright reissued a “buy” rating and issued a $12.00 price target on shares of Sana Biotechnology in a research note on Thursday, May 9th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $12.75.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.